Pharmafile Logo

Neurocrine Biosciences Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Neurocrine Biosciences Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Neurocrine Biosciences Inc.

Recent articles on PMLiVE featuring Neurocrine Biosciences Inc

- PMLiVE
Reaching patients and HCPs during the pandemic

COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels

- PMLiVE
AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership’s end

- PMLiVE
Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn’t able to improve on placebo

- PMLiVE
AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

- PMLiVE
Myovant’s fibroids drug clears phase 3 trial, but shares sink

Investors concerned on how it stacks up against AbbVie rival

- PMLiVE
Teva will have to endure revenue ‘trough’ in 2019

Company looks to migrane treatment Ajovy for growth

- PMLiVE
AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

First new oral treatment in more than 10 years

- PMLiVE
FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

- PMLiVE
Neurocrine bags FDA approval for first tardive dyskinesia drug

Ingrezza edges ahead of Teva’s rival drug Austedo

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month’s pharma deals round-up

- PMLiVE
FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE
Neurocrine plans movement disorder drug filing in 2016

NBI-98854 in trials for tardive dyskinesia

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links